ORIC Pharmaceuticals Q3 Results Highlight Clinical Pipeline Strength
SOUTH SAN FRANCISCO, CA — November 13, 2025 — ORIC Pharmaceuticals reported its third-quarter 2025 financial and clinical results,...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
SOUTH SAN FRANCISCO, CA — November 13, 2025 — ORIC Pharmaceuticals reported its third-quarter 2025 financial and clinical results,...
New York, October 30, 2025 — Pfizer Inc. (NYSE: PFE) has issued a strong response to what it calls...
